EADV Congress 2026 Poster Presentation: Staphylococcus aureus Toxins: Mechanisms of Action Cause Inflammation and Pruritus in Atopic Dermatitis NEWS PROVIDED BY Alphyn Biologics September 30, 2026, 9:00 ET CONTACTS Corporate: Neal Koller nkoller@alphynbiologics.com (410) 690-8687 Media: Susan Thomas susan@endpointcommunications.net (619) 540-9195
Society for Pediatric Dermatology Annual Meeting Poster Presentation: Zabalafin, a novel topical antiviral drug for the treatment of Molluscum contagiosum NEWS PROVIDED BY Alphyn Biologics July 23, 2026, 10:00 ET CONTACTS Corporate: Neal Koller nkoller@alphynbiologics.com (410) 690-8687 Media: Susan Thomas susan@endpointcommunications.net (619) 540-9195
25th Annual ESPD Congress Poster Presentation: The importance of S. aureus as a contributor to the etiology of pediatric atopic dermatitis NEWS PROVIDED BY Alphyn Biologics April 28, 2026, 03:00 ET CONTACTS Corporate: Neal Koller nkoller@alphynbiologics.com (410) 690-8687 Media: Susan Thomas susan@endpointcommunications.net (619) 540-9195
Alphyn Completes Enrollment in Phase 2 Trial of Topical Therapy for Molluscum Contagiosum NEWS PROVIDED BY Alphyn Biologics Mar 24, 2026, 07:30 ET Company’s patented multi-target therapeutics® platform establishes a new class of patient-friendly treatments ANNAPOLIS, Md., March 24, 2026 /PRNewswire/ — Alphyn Biologics, Inc., a clinical-stage dermatology company developing the first Multi-Target Therapeutics® drug…
Alphyn Completes Enrollment in CLEAR-AD1 Global Phase 2b Clinical Trial of Novel Topical for Atopic Dermatitis NEWS PROVIDED BY Alphyn Biologics Mar 11, 2026, 07:30 ET Multi-target therapeutic aims to treat all key and interconnected problems of atopic dermatitis ANNAPOLIS, Md., March 11, 2026 /PRNewswire/ — Alphyn, a clinical-stage dermatology company developing the first Multi-Target…